Increases in resting heart rate are a recognised class effect of incretin-based therapies and have been reported with GLP-1 receptor agonists more broadly, as reflected in the Summary of Product Characteristics (SmPC) for licensed agents such as semaglutide (Wegovy) and liraglutide (Saxenda)
Short-term studies might use higher acute doses, while long-term studies require careful consideration of sustained exposure and potential adaptations to the 5-Amino-1MQ dosage over time
Related Resources Explore additional peptide therapy resources to optimize your metabolic health journey: Semaglutide GLP-1 receptor agonist for appetite control and glucose regulation Tirzepatide Dual GIP/GLP-1 agonist for enhanced metabolic support CJC-1295/Ipamorelin Growth hormone secretagogue for muscle preservation and recovery Tesamorelin GHRH analog targeting visceral adipose tissue reduction Schedule a Peptide Therapy Consultation Discuss your metabolic optimization goals with our medical team
Its primary ghk-cu benefits stem from its ability to orchestrate a complex, multi-faceted healing response
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and meta-analysis (BMJ)
This contrasts markedly with full-length growth hormone, which can impair glucose tolerance and potentially precipitate or worsen diabetes
